AMDX-2011P for Alzheimer's Disease
Trial Summary
What is the purpose of this trial?
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. Please consult with the trial investigators for more details.
What data supports the idea that AMDX-2011P for Alzheimer's Disease is an effective treatment?
The available research does not provide any specific data on the effectiveness of AMDX-2011P for Alzheimer's Disease. Instead, it discusses other treatments like donepezil and acetyl-L-carnitine. Donepezil has been shown to be effective in both mild to moderate and more severe stages of Alzheimer's Disease, while acetyl-L-carnitine showed potential benefits for younger patients with early-onset Alzheimer's. However, there is no information on AMDX-2011P in the provided research.12345
What safety data is available for AMDX-2011P in Alzheimer's treatment?
The provided research does not mention AMDX-2011P or its variants directly. Therefore, no specific safety data for AMDX-2011P is available in the given studies. The studies focus on other treatments like LY451395, AL-108, idalopirdine, and AVP-786, each with their own safety profiles, but none of these are identified as AMDX-2011P.46789
Research Team
David Bingaman, DVM, PhD
Principal Investigator
Amydis Inc.
Eligibility Criteria
This trial is for individuals with Alzheimer's Disease confirmed by a PET brain scan. Participants must be willing to undergo genetic testing and retinal imaging, and have the ability to fixate during these procedures. Those with heart rhythm issues, significant ECG abnormalities, psychological conditions likely to prevent study completion, glaucoma or certain forms of macular degeneration cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single intravenous bolus injection of AMDX-2011P followed by safety assessments, retinal imaging, and PK blood collection
Follow-up
Participants are monitored for safety and effectiveness after treatment, including detection of amyloid deposits in the retina
Treatment Details
Interventions
- AMDX-2011P
Find a Clinic Near You
Who Is Running the Clinical Trial?
Amydis Inc.
Lead Sponsor